There is no product in the shopping cart, buy it!
Looking for effective tools to explore the role of glycosylation in biological systems? Creative Biolabs offers a diverse range of glycoengineered cell lines using precise overexpression and knockout techniques. Our specially glycan-modified cell lines, which include CHO, 293 cells, and around 800 tumor-derived lines, offer valuable opportunities to study the changes in glycosylation that may affect a variety of diseases. These include, but are not limited to, cancers such as melanoma, bladder urothelial carcinoma, conditions like acute myeloid leukemia (AML), and meningothelial tumors. Using these glycoengineered cells, researchers are empowered to meticulously dissect the functional sequelae arising from precisely defined glycosylation modifications, capitalizing on a dual offering of both immediately accessible and bespoke, custom-engineered cellular models tailored to specific research inquiries.
These cell lines exhibit increased expression of certain glycosyltransferases or other enzymes critical to glycan biosynthesis. This allows for the study of the functional impact of increased levels of specific glycans on cellular behavior, signaling pathways, and interactions with other molecules.
Applications include:
Fig.1 Illustration of key segments of the N-glycosylation pathway in murine myeloma cell lines and CHO cells.1
These cell lines have specific glycosylation-related genes knocked out, leading to the absence or significant reduction of particular glycan structures. This enables the direct assessment of the functional roles of these glycans. Applications include:
A: We provide a range of overexpression cell lines, including those with increased expression of glycosyltransferases, glycosidases, and other proteins that play a role in glycan synthesis and modification. If you're looking for a specific target, don't hesitate to get in touch with us.
A: Our knockout cell lines are made using advanced gene editing tools like CRISPR-Cas9, which allow us to precisely knock out the target gene.
A: Yes! We offer custom glycoengineering services. Just let us know the specific details of the cell line and modification you need, and we'll be happy to assist you in creating it.
A: We employ a range of molecular biology techniques, such as PCR, Western blotting, flow cytometry, and NGS, to confirm the genetic modification and its impact on protein expression. Glycan analysis can also be performed to verify changes in glycosylation profiles.
Except for our overexpression and knockout glycoengineered cell products, Creative Biolabs offers comprehensive glycoengineering services to further support your research in glycobiology and glyco-chemistry, including but not limited to:
Contact us today to discuss how our glycoengineered cell solutions can accelerate your research endeavors.
Reference
| Cat | Product Name | Cell Line | Target | Size | Datasheet | Inquiry |
|---|---|---|---|---|---|---|
| GLJF-0925-JF748 | GlycoFlux™ Human GCK Overexpression Jurkat Cell Line | Jurkat cell line | GCK | 1 M cells/vial*2 | ||
| GLJF-0925-JF750 | GlycoFlux™ Human GPHB5 Overexpression Jurkat Cell Line | Jurkat cell line | GPHB5 | 1 M cells/vial*2 | ||
| GLJF-0925-JF753 | GlycoFlux™ Human GSK3B Overexpression Jurkat Cell Line | Jurkat cell line | GSK3B | 1 M cells/vial*2 | ||
| GLJF-0925-JF755 | GlycoFlux™ Human GYG2 Overexpression Jurkat Cell Line | Jurkat cell line | GYG2 | 1 M cells/vial*2 | ||
| GLJF-0925-JF758 | GlycoFlux™ Human HK1 Overexpression Jurkat Cell Line | Jurkat cell line | HK1 | 1 M cells/vial*2 | ||
| GLJF-0925-JF760 | GlycoFlux™ Human ILKAP Overexpression Jurkat Cell Line | Jurkat cell line | ILKAP | 1 M cells/vial*2 | ||
| GLJF-0925-JF761 | GlycoFlux™ Human LCMT1 Overexpression Jurkat Cell Line | Jurkat cell line | LCMT1 | 1 M cells/vial*2 | ||
| GLJF-0925-JF762 | GlycoFlux™ Human LDHA Overexpression Jurkat Cell Line | Jurkat cell line | LDHA | 1 M cells/vial*2 | ||
| GLJF-0925-JF763 | GlycoFlux™ Human LDHAL6A Overexpression Jurkat Cell Line | Jurkat cell line | LDHAL6A | 1 M cells/vial*2 | ||
| GLJF-0925-JF764 | GlycoFlux™ Human LDHAL6B Overexpression Jurkat Cell Line | Jurkat cell line | LDHAL6B | 1 M cells/vial*2 | ||
| GLJF-0925-JF765 | GlycoFlux™ Human LDHB Overexpression Jurkat Cell Line | Jurkat cell line | LDHB | 1 M cells/vial*2 | ||
| GLJF-0925-JF766 | GlycoFlux™ Human LDHC Overexpression Jurkat Cell Line | Jurkat cell line | LDHC | 1 M cells/vial*2 | ||
| GLJF-0925-JF767 | GlycoFlux™ Human LDHD Overexpression Jurkat Cell Line | Jurkat cell line | LDHD | 1 M cells/vial*2 | ||
| GLJF-0925-JF768 | GlycoFlux™ Human MGAM Overexpression Jurkat Cell Line | Jurkat cell line | MGAM | 1 M cells/vial*2 | ||
| GLJF-0925-JF769 | GlycoFlux™ Human MGAM2 Overexpression Jurkat Cell Line | Jurkat cell line | MGAM2 | 1 M cells/vial*2 | ||
| GLJF-0925-JF770 | GlycoFlux™ Human PCK1 Overexpression Jurkat Cell Line | Jurkat cell line | PCK1 | 1 M cells/vial*2 | ||
| GLJF-0925-JF771 | GlycoFlux™ Human PCK2 Overexpression Jurkat Cell Line | Jurkat cell line | PCK2 | 1 M cells/vial*2 | ||
| GLJF-0925-JF772 | GlycoFlux™ Human PDE3A Overexpression Jurkat Cell Line | Jurkat cell line | PDE3A | 1 M cells/vial*2 | ||
| GLJF-0925-JF773 | GlycoFlux™ Human PDK2 Overexpression Jurkat Cell Line | Jurkat cell line | PDK2 | 1 M cells/vial*2 | ||
| GLJF-0925-JF774 | GlycoFlux™ Human PDK3 Overexpression Jurkat Cell Line | Jurkat cell line | PDK3 | 1 M cells/vial*2 |